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Abstract
Activated macrophages contribute to chronic inflammation
by the secretion of cytokines and proteinases. Tumor necro-
sis factor a (TNFa) is particularly important in this process
because of its ability to regulate other inflammatory media-
tors in an autocrine and paracrine fashion. The mecha-
nism(s) responsible for the cell type-specific regulation of
TNFa is not known. We present data to show that the ex-
pression of TNFa is regulated by the transcription factor
C/EBP/3 (NF-IL6). C/EBP/3 activated the TNFa gene pro-
moter in cotransfection assays and bound to it at a site
which failed to bind the closely related protein C/EBPa.
Finally, a dominant-negative version of C/EBP/3 blocked
TNFa promoter activation in myeloid cells. Our results im-
plicate C/EBPfi as an important regulator ofTNFa by mye-
lomonocytic cells. (J. Clin. Invest. 1994. 94:1449-1455.) Key
words: transcription factor * cytokine * promoter * inflam-
mation
Introduction
Activated macrophages produce an array of inflammatory cyto-
kines including tumor necrosis factor a (TNFa), interleukins-
1, -6, and -8, macrophage chemotactic protein-i, and macro-
phage inflammatory protein la (MIP-la)' (1-6). Many of
these cytokines are capable of both attraction and activation of
additional inflammatory cells and induction of angiogenesis
(7). In addition, in chronic inflammation, such as rheumatoid
arthritis, macrophages contribute directly to joint destruction by
producing proteases, such as collagenase (matrix metallopro-
teinase 1) and stromelysin (matrix metalloproteinase 3) (8, 9).
TNFa may play a crucial role in the inflammatory process,
since it is capable of inducing cytokines and matrix metallopro-
teinases in an autocrine and paracrine fashion (10, 11).
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A variety of stimuli can induce cells to produce TNFa,
including infection by viruses or other agents, interaction with
adhesion molecules, or treatment with phorbol esters, endotox-
ins, or cytokines such as IL-1 or even TNFa itself (12-14).
Examination of the upstream promoter region of the human
TNFa gene has revealed both cell type- and stimulus-specific
regulatory elements, including potential binding sites for the
transcription factors NF-KB and AP-1 ( 15-22). Although many
cell types including lymphocytes, smooth muscle cells, mast
cells, and others are capable ofTNFa synthesis, activated mono-
cytes/macrophages are the principal source of TNFa (12).
Nonetheless, little is known about how the TNFa gene is regu-
lated in a cell type-specific fashion.
C/EBP,6 (CCAAT/enhancer binding protein P, also called
NF-IL6, NF-M, LAP, IL6-DBP, AGP/EBP, and CRP2) is a
member of a family of transcription factors termed bZip proteins
which have a basic DNA-binding domain linked to a leucine
zipper dimerization motif. It is closely related to the founding
member of this family, C/EBPa, which has been shown to be
intimately involved in the regulation of adipocyte differentiation
(23). Earlier studies identified monocytes and macrophages as
the principal source of C/EBP/3 (24, 25). Cell type-specific
gene regulation by C/EBP/3 has been shown to depend on
interactions with other transcription factors, such as NF-KB, c-
jun, the glucocorticoid receptor, and the nuclear oncoprotein v-
Myb (26-29). In addition, binding sites for C/EBPP have been
identified in the promoters for a large number of cytokine genes
which are expressed in myeloid cells, including the genes for
interleukins-1, -6, and -8, MIP-la, and chicken monocyte
growth factor (cMGF) (24, 30-35), suggesting that the factor
may be an important activator of inflammation and of growth
regulatory genes. Finally, ectopic expression of Myb and C/
EBP/3 has been shown to induce the expression of myeloid-
specific genes in heterologous cell types, implicating C/EBP/3
as a key regulator of myeloid cell differentiation (27).
In this paper, we have investigated the relationship between
C/EBP/3 activity and TNFa expression. We identified a specific
binding site for C/EBP/3 in the TNFa gene promoter, sug-
gesting that C/EBP/3 directly regulates the expression of the
cytokine. We tested this in cotransfection assays and found
that C/EBP/6, more strongly than C/EBPa, activated a TNFa
promoter-reporter construct. Furthermore, ectopic expression
of a dominant-negative form of C/EBP,6 was able to block
activation of the TNFa promoter by endogenous transcription
factors. Our results demonstrate that C/EBP,6 is an important
regulator of the TNFa gene and that it is responsible for the cell
type-specific regulation of the TNFa gene in myelomonocytic
cells.
Methods
Cell lines. The human myelomonocytic cell lines U937 and THP-1 and
the Jurkat human T cell line were obtained from the American Type
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Culture Collection (Rockville, MD) and were maintained in RPMI me-
dium supplemented with 10% heat-inactivated fetal bovine serum, gluta-
mine, penicillin, and streptomycin. HD-l 1, an MC29 virus (v-myc onco-
gene) transformed chicken macrophage cell line, was maintained in
Dulbecco's modified Eagle's medium supplemented with 8% fetal bo-
vine serum, 3% chicken serum, glutamine, and antibiotics as above.
Plasmids. The human C/EBP/3 expression vector (hC/EBP,3),
which expresses the NF-IL6 cDNA under control of the cytomegalovirus
(CMV) promoter (from S. Akira, Osaka University, Japan), has been
described (24), as have similar plasmids that express full-length chicken
C/EBPP (cC/EBP/3, also referred to as NF-M) and the 5D229 domi-
nant-negative deletion mutant (27, 31). The latter plasmid expresses a
protein having an NH2-terminal deletion so that only the last 229 amino
acids remain. This protein is 92% identical and 99% homologous to its
human counterpart, and the COOH-terminal 212 amino acids, represent-
ing the DNA binding and leucine zipper domains, are 99% identical.
The TNFa promoter-luciferase reporter plasmids have been described
(15, 22). The pCDM8 expression vector plasmid was purchased from
Invitrogen (San Diego, CA).
Transfections and reporter gene assays. Jurkat T cells were
transfected using DEAE-dextran as follows. On the day before transfec-
tion, the cells were split to - 0.7 x 106 cells/ml. For each sample, -1
x 107 cells were washed twice, then resuspended in 2 ml STBS (25
mM Tris/HCl, pH 7.5, 137 mM NaCl, 5 mM KCl, 0.6 mM Na2PO4,
0.7 mM CaCl2, and 0.5 mM MgCl2) containing 750 Mg/ml DEAE-
dextran and a total of 15 .g of CsCl-purified plasmid DNA (specific
plus carrier), for 30 min at 37°C, with gentle inversion every 5 min.
The cells were then collected by centrifugation, resuspended in fresh
medium, and allowed to recover for 3-5 h before treatment with 20
ng/ml PMA (Sigma Chemical Co., St. Louis, MO) as indicated. Cells
were harvested 18-24 h later. The U937 cells were transfected by
electroporation as described previously (15), using an electroporation
apparatus from Invitrogen. DEAE-dextran-mediated transfection of
HD-11 cells and luciferase assays have been described (27, 31). All
transfection results were normalized for protein content, as determined
using an assay reagent from Bio-Rad Laboratories (Richmond, CA).
All experiments were performed a minimum of three times, and similar
results were obtained using independent preparations of DNA.
Electrophoretic mobility shift assays (EMSAs). Nuclear extracts
were obtained from U937, THP-1, and Jurkat cells as described (36).
All buffers were supplemented with PMSF (20 yiglpl), aprotinin, pep-
statin A, and leupeptin (each 5t g/ml). For expression in insect cells,
the cC/EBPf3 CDNA was transferred to the transfer vector pVL1392
and transfected into Sf9 cells along with linearized Baculovirus DNA
using a kit from PharMingen (San Diego, CA). The resulting virus was
used to infect new Sf9 or High-5 cells, and nuclear extracts were pre-
pared 2 d later as follows. All buffers were chilled and supplemented
with protease inhibitors as described above. The cells were collected,
washed twice with PBS, and resuspended in Tris-X buffer (20 mM
Tris-Cl, pH 7.3, 50 mM KCl, 1 mM EDTA, 1.5 mM MgCl2, and 0.5
mM CaCl2) at a concentration of 1 x 107/ml. The cells were lysed by
adding NP-40 to a final concentration of 0.5%, then the nuclei were
recovered by centrifugation, resuspended at fourfold higher concentra-
tion of Tris-X buffer plus 0.3 M KCl, left 5 min on ice, and then
centrifuged again. The supernatant was diluted with three volumes of
Tris-X buffer (to make 0.085 M KC1 final), and centrifuged again, and
the resulting nuclear extract was stored at -80°C. Bacterially expressed,
purified rat C/EBP,/ (rC/EBP,6) and rat C/EBPa (rC/EBPa) proteins
were generously provided by P. Johnson (National Institutes of Health,
Bethesda, MD). Bacterially expressed human NF-KB1 (p50) was pur-
chased from Promega Corp. (Madison, WI).
The methods for radiolabeling the double-stranded oligonucleotide
probes using Klenow polymerase and [a_ 32p] dCTP and for performing
the EMSAs have been described (27). Where indicated, antibodies or
excess unlabeled competitor oligonucleotides were incubated with the
proteins or nuclear extracts for 20 min on ice before the addition of the
probe. The samples were then incubated for an additional 20 min before
electrophoresis on nondenaturing polyacrylamide gels. Antibodies spe-
cific for hC/EBP,3, cC/EBP/3, and rC/EBP,6 were obtained from S.
Akira, A. Leutz, and P. Johnson, respectively.
Synthetic oligonucleotides. The following synthetic oligonucleotides
were used to generate the -130/+35 TNFa radiolabeled EMSA probe
using the polymerase chain reaction: forward, 5 '-GGCCCACTACCG-
CTTCCTC-3'; reverse, 5 '-CCTCTGCTGTCCTfGCTGA-3'. The fol-
lowing radiolabeled oligonucleotides were used as probes in EMSAs:
the - 100/-74 C/EBP/3 binding site of the TNFa promoter, 5'-TCG-
ACATGGGTTTCTCCACCAAGGAAGl1TllC-3', 3 '-GTACCCAA-
AGAGGTGGT7CCTTCAAAAGAGCT-5', the C/EBP,3 binding se-
quence from the IL-6 promoter (24), 5 '-TCGAGACATTGCACA-
ATCTG-3', 3 '-CTGTAACGTCTTAGACAGCT-5', and the Ig/HIV
promoter binding sequence for NF-KB (37), 5'-TCGAGAAGGGAC-
TTrCCGCTGGGGACTTTCCAGGGC-3 ', 3 '-CYICCCTGAAAGG-
CGACCCCTGAAAGGTCCCGAGCT-5'.
DNaseIfootprinting. The -615 TNFa-luciferase plasmid was di-
gested with XhoI, radiolabeled by end-filling using Klenow polymerase
and [a-32P]dCTP, and then further digested with HindIll. The resulting
fragment containing the TNFa promoter was purified after agarose gel
electrophoresis using Geneclean (BiolOl) and subjected to DNaseI foot-
printing as described (38).
Results
C/EBP,3 activates the TNFa promoter. The TNFa promoter
has been shown to be strongly activated by treatment with PMA
(15, 22), an activator of protein kinase C which also activates
C/EBP,6 activity (31, 39). We used transient transfection
assays to determine whether C/EBPP could cooperate with
PMA treatment to activate the TNFa promoter. We chose the
Jurkat human T cell line, which normally does not express either
C/EBPf3 or TNFa, under the conditions used in our assays
(data not shown). A series of TNFa promoter-luciferase re-
porter gene constructs, containing portions of the promoter ex-
tending from just downstream to several hundred nucleotides
upstream of the transcription start site (22), were transfected
into Jurkat cells either with a control plasmid or with a plasmid
expressing hC/EBPf3, under the control of the constitutive
CMV promoter. Parallel experiments were performed with and
without PMA treatment. As shown in Fig. 1, none of the TNFa
promoter constructs were expressed at significant levels in the
absence of PMA treatment, even in the presence of hC/EBP/,
and none were significantly activated by PMA treatment alone.
However, PMA treatment of cells expressing C/EBPO led to
strong activation of all but the shortest promoter constructs
tested (-36 bp from the transcription start site), suggesting
that PMA and C/EBPB acted cooperatively to induce TNFa
promoter activity. In addition, the data suggest that crucial
PMA- and C/EBP,/-responsive elements must lie in the region
bounded by positions -95 and -36 in the TNcFa promoter.
The promoter construct extending only to position -95 was
consistently less active than the longer versions (-120 and
-295), suggesting that an important regulatory element(s)
might lie near the -95 site in the promoter.
C/EBP,3 binds a specific site in the TNFa promoter. The
experiments described above suggested that C/EBP/3 could reg-
ulate the TNFa promoter. An EMSA was used to determine
whether the promoter contained a bona fide C/EBPf? binding
site. Based on our results with the promoter-reporter gene con-
structs (see above), we generated a radiolabeled fragment of
the TNFa promoter bounded by positions -130 to +35 relative
to the transcription start site. Fig. 2 A shows an EMSA experi-
ment in which such an oligonucleotide was efficiently bound
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Figure 1. C/EBP/3 activates the
TNTFa promoter. Transfections of
Jurkat T cells were performed as
described in Methods, using 0.5
jig of the hC/EBP/3 plasmid and
3 jig of the indicated TNFa pro-
moter reporter construct. On the
left of the bar graphs are dia-
grammed the TNFa reporter-lu-
ciferase constructs used. Potential
binding sites for a number of tran-
scription factors are indicated by
labeled boxes. The relative light
units have been corrected for the
460 total protein in the cell lysates.
Similar results have been obtained
in > 10 experiments and with dif-
ferent plasmid preparations.
by insect cell-expressed chicken C/EBPJ (cC/EBP,6). Bind-
ing was inhibited completely by the addition of excess oligonu-
cleotide containing the C/EBP/3-binding site from the human
IL-6 promoter, and the addition of antibodies specific for cC/
EBPP resulted in a "supershift" of the protein-DNA complex
(not shown), demonstrating the specificity of the binding reac-
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Figure 2. C/EBPJ binds
to the human TNFa pro-
moter. (A) Binding of C/
EBP,/ to the -130/+35
TNFa promoter oligonu-
cleotide. Lanes 1-5 rep-
resent increasing quanti-
ties (0.5-3 .LI) of cC/
Bound EBP,3, which was ex-
pressed in Baculovirus-
infected insect cell nu-
clear extracts. The posi-
tions of free and C/
EBP,6-bound oligonu-
cleotides are indicated.
(B) DNaseI footprinting
of the TNFa promoter.
Binding and footprint re-
Free actions are described in
Methods. The lanes that
received the THP-l nu-
clear extracts (Nucl. Ex-
tract), the immune anti-
hC/EBP/3 (I), or control
nonimmune serum (N)
are indicated at the top of
the figure. The -102 and
-84 represent the base
pair distance 5' of the
transcription start site de-
termined using size stan-
dards (not shown). The
DNaseI hypersensitive
site, located at -90 bp
from the transcription
start site, is identified by
the arrow on the right.
tion. Similar complexes were also formed using nuclear extracts
from the human myeloid cell line THP-1 (not shown). These
results suggest that C/EBP/3 could play a direct role in the
regulation of the TNFa promoter.
A DNaseI footprint assay was used to more precisely local-
ize the binding sites for C/EBPP on the TNFa promoter. How-
ever, as shown in Fig. 2 B, the addition of THP-1 nuclear
extracts to an end-labeled fragment of the TNFa promoter re-
sulted in the formation of a new DNaseI hypersensitive site at
position -90 relative to the start site of transcription, rather
than a discrete protected region. These results suggest that the
extracts contained a protein or complex that specifically inter-
acted with this region of the promoter. Addition of antibodies
specific for hC/EBP,3, but not nonimmune serum, blocked the
hypersensitive site formation, indicating that C/EBPP, or a pro-
tein complex containing C/EBPB, was responsible for this
change in the DNaseI sensitivity of the promoter.
Two potential C/EBP/3-binding sites, in opposite orienta-
tions, were noted extending from -97 to -79 bp relative to the
transcription start site of the TNFa promoter, which conformed
at 9 of 12 positions to the consensus C/EBP,6-binding site, T(T/
G)NNGNAA(T/G) (24). As shown in Fig. 3, insect cell-
expressed cC/EBPJ3 protein bound efficiently to a radiolabeled,
synthetic 26-mer oligonucleotide containing this site. Again, C/
EBP/3 binding was inhibited completely when an excess of
either unlabeled oligonucleotide used as the probe or one con-
taining a previously identified C/EBPJ-binding site from the
human IL-6 gene promoter was included. The complex was
not inhibited by an unlabeled NF-KB binding oligonucleotide
representing the Ig/HIV promoter (not shown), even though
the oligonucleotide used as the probe contained a previously
characterized binding site for NF-KB (data not shown; 17).
Addition of antibodies specific for cC/EBP/3, but not control
antibodies, resulted in a supershift of the protein-DNA com-
plex. Similar results have also been obtained using recombinant,
purified rat C/EBP,/ (rC/EBP,/) (Fig. 4 A; data not shown).
Although C/EBP/3 bound quite efficiently to the TNFa pro-
moter-derived binding site, the oligonucleotide derived from
the IL-6 promoter was a better competitor when the - 100/-74
TNFa oligonucleotide was used as probe, suggesting that the
binding site in the TNFa promoter was relatively weak. We
conclude that C/EBP,/ regulates the human TNFa gene pro-
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Figure 3. Binding of cC/
EBPl6 to the -100/-74
human TNFa promoter
Comoetitors Sgra oligonucleotide. The
EMSA was performedC IL-6 TNF TNF N with Baculovirus-ex-
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IJx5x50pressed cC/EBP,/ and
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-100/-74 TNFa pro-
moter oligonucleotide.
hAs , a The competitors included
an unlabeled, irrelevant,
Bound control oligonucleotide(C), and unlabeled oh-
gonucleotides repre-
senting the C/EBPB-
binding site of the IL-6
promoter (IL-6) and that
used as the radiolabeled
probe (TNF) (lanes 1-
4). These competitors
were used at 50- or 500-
fold excess as indicated
in the figure. Nonim-
mune (N) or immune
(I), anti-cC/EBP,/, rab-
Free _ bit antisera were in-
cluded where indicated
2 3 4 5 6 (lanesSand6).
moter by binding directly to a specific site and activating its
transcription.
Selectivity of binding to -1001-74 TNFa oligonucleotide.
C/EBPB and C/EBPa are both expressed in macrophage cell
lines and are capable of heterodimerization and of binding to
the same oligonucleotides (40-42). We next examined the abil-
ity of C/EBPa and C/EBPB to interact differently with the
TNFa promoter. Using an EMSA, purified recombinant C/
EBP/3 and C/EBPa both bound strongly to the oligonucleotide
derived from the IL-6 promoter (Fig. 4 A). Binding by both
isoforms to the IL-6 probe was inhibited by excess unlabeled
IL-6, but not TNFa, promoter oligonucleotide. Similar results
have been observed previously with oligonucleotides derived
from the cMGF promoter (31, 43). In contrast, only C/EBPf3
bound to the - 100/-74 TNFa oligonucleotide, suggesting that
the site was specific for only one member of this highly related
family of bZip proteins (Fig. 4 A).
A cotransfection assay was used to test whether both bZip
proteins could activate the TNFa promoter. Jurkat T cells were
cotransfected with TNFa or cMGF promoter-reporter con-
structs, plus either C/EBPl or C/EBPa expression vectors.
Transfected cells were then treated with PMA. Both transcrip-
tion factors activated the cMGF promoter to approximately
equal levels (Fig. 4 B). In contrast, C/EBPB was a stronger
activator of the TNFa promoter than C/EBPa, consistent with
its stronger binding in the EMSA. When C/EBPa was coex-
pressed with C/EBPf3, the activation of the TNFa promoter was
comparable with that observed with C/EBP,6 alone, suggesting
either that C/EBPa/(3 heterodimers were as active as C/EBP/3
homodimers or that C/EBPI3 was somehow dominant.
Dominant-negative C/EBP/3 inhibits the TNFa promoter.
Overexpression of C/EBPP could affect the regulation of the
TNFa promoter in two ways, either by binding to the promoter
and directly activating its transcription or by interfering with
negative-regulatory effects of other bZip proteins such as C/
EBPa, perhaps by forming inactive heterodimers (42). This
was tested using a truncated, dominant-negative (DN) version
of the chick C/EBPI3 protein (27, 31), termed DN229. This
version of C/EBPf3 only contains the COOH-terminal 229-most
amino acids. It therefore lacks the transactivation domain, leav-
ing the dimerization and DNA-binding domains intact. It is
capable of binding DNA, but has no transactivation activity,
and forms inactive heterodimers with other C/EBP-like proteins
(31 ). The DN229 construct has been shown to be quite effective
at suppressing the expression of other C/EBP,3-regulated genes,
such as the cMGF and mim-1 genes (27, 31 ). When compared
with control expression vectors without an insert, cotransfection
of the DN229 plasmid was quite effective at inhibiting the
ability of hC/EBPP to activate the TNFa promoter in Jurkat
cells, even though the cells were treated with PMA (Fig. 5).
This indicates that the DN229 construct is not only unable to
activate the TNFa promoter, but that expression of a truncated
form of C/EBPJ3 blocks activation by the full-length protein.
A similar experiment was performed using the human mye-
lomonocyte cell line U937, which expresses endogenous C/
EBP,6 protein and secretes a high concentration of TNFa in
response to PMA (data not shown) to determine whether ectopi-
cally expressed DN229 could likewise block the expression of
the TNFa promoter in myeloid cells. Fig. 6 shows that the
TNFa promoter construct extending to position -120, the con-
struct that consistently provided the greatest activation, was
moderately active when transfected into U937 cells and that its
expression was stimulated three- to fivefold when the cells were
treated with PMA. (Similar results were obtained with other
myeloid cell lines, including human THP-1 and chicken HD-
11 cells.) Expression of the dominant-negative form of C/EBP/6
(DN229) not only blocked activation by PMA, but also inhib-
ited TNFa promoter activity to below basal levels. In contrast,
the control plasmid containing only the CMV promoter had
no effect on the activity of the TNFa promoter-reporter gene
construct. We conclude that the human TNFa promoter is di-
rectly regulated by C/EBPP, most probably by binding to the
region between -95 and -36 relative to the transcription start
site.
Discussion
Activation of TNFa has been implicated in a wide variety of
responses to inflammatory and infectious agents, and it is known
to be highly expressed by activated macrophages, such as those
found in the synovial lining of rheumatoid joints (44, 45). The
results in this paper demonstrate that the transcription factor C/
EBP,3 is a key regulator of the TNFa gene. We have identified
a specific C/EBP,6L-binding site in the TNFa promoter, shown
that the promoter responds dramatically to the expression of C/
EBP/3, and used a dominant-negative version of C/EBPJ to
inhibit the activation of the TNFa promoter.
The C/EBP/B-binding site identified by DNaseI footprinting
and EMSA experiments maps to positions - 100/-74 of the
human TNFa promoter. However, compared with the oligonu-
cleotide from the IL-6 promoter, C/EBPP bound the -100/
-74 site relatively weakly. Nevertheless, in DNasel foot-
printing assays, which are generally much less sensitive than
EMSAs, myeloid cell extracts induced the formation of a DNa-
sel hypersensitive site on the TNFa promoter at position -90,
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Figure 4. The TNFa promoter is specific for C/EBP/5. (A) Selective binding of CIEBP,6, but not C/EBPa, to the - 100/-74 TNFa promoter.
The EMSA was performed with recombinant, purified rC/EBPa (lanes 3-6) and rC/EBP/3 (lanes 1, 2, and 7-9), as indicated at the top of the
figure. The radiolabeled probes, which included the C/EBPI3-binding site of the IL-6 promoter (IL-6) and the - 100/ -74 TNFa promoter (7NF)
oligonucleotides, and the competitor oligonucleotides, used at 100-fold excess, are also indicated at the top of the figure (symbols as in Fig. 3).
Nonimmune (N) or monospecific, immune anti-rC/EBP,6 (I) sera were added where indicated. The mobilities of the C/EBPa and C/EBP#? bound
and the free, unbound radiolabeled -100/-74 TNFa oligonucleotide are indicated on the left of the figure. (B) C/EBP,6 preferentially activates
the TNFa promoter. Jurkat cells were transfected as described in Methods. They were cotransfected with the TNFa-luciferase (3 Iag) or with
cMGF-luciferase (4.5 jig) constructs and with the hC/EBP,6 or the rC/EBPa expression vectors in the concentrations indicated at the bottom of
the figure. Where indicated, both C/EBPa and C/EBP,/ were cotransfected at equal concentrations. The fold increase represents the fold increase
over baseline induced by PMA. These experiments were repeated twice with similar results.
and this activity was inhibited by C/EBP,6-specific antisera.
Thus, in the context of a nuclear extract, the C/EBP5 appears
to interact with a relatively high affinity for the promoter, sug-
gesting that the factor may be part of a multiprotein complex
which binds the TNFa promoter in myeloid cells.
The TNFa promoter was differentially recognized by C/
EBP/3 and C/EBPa. Purified recombinant C/EBPf3, but not Cl
EBPa, bound to the TNFa promoter oligonucleotide in EMSA
assays. Consistent with this difference, C/EBP6 was consider-
ably more active than C/EBPa at activating the TNFa promoter
construct. As a control, the cMGF promoter, which readily binds
both C/EBP proteins, was activated equally well by each. Both
C/EBPa and C/EBP,6 are expressed in myelomonocytic cell
lines, however, C/EBPa decreased while C/EBP/ increased
with differentiation and activation (40, 41). These data suggest
that the differential binding of the two transcription factors
may be important in the regulation of TNFa in monocytes/
macrophages where both bZip proteins are expressed.
The importance of the region of the TNFa promoter that
contains the C/EBP/3-binding site (at position -90) hag also
been noted by others. For example, three copies of a 43-nucleo-
tide-long fragment of the promoter spanning this site was suffi-
cient to confer both elevated basal and TNFa-inducible activity
to an otherwise minimally active heterologous promoter (21).
More recently, a cyclosporin A- and FK506-sensitive factor in
the murine T cell line Ar-S was identified that functions through
a portion of the promoter overlapping the C/EBPfl-binding site
( 17). Of interest, the -90 site is adjacent to a potential binding
site for NF-KB ( 17, 24), which has been shown to interact with
C/EBP/3 in vitro (26, 29). In addition, both C/EBP/3 and NF-
KB bound to the IL-6 and the IL-8 gene promoters, and the
ratio of the two factors appeared to regulate the activities of
those genes (34, 46). Our own preliminary data suggest that
overexpression of NF-KB 1 or RelA may inhibit C/EBPP-medi-
ated activation of the TNFa promoter in Jurkat cells (Pope, R.,
and S. A. Ness, unpublished observations). Further work will
be required to determine whether these two transcription factors
interact to regulate the TNFa gene.
An interesting feature of TNFa gene regulation in Jurkat
cells was its apparent dependence on both C/EBP/3 and PMA
treatment, which presumably participates by stimulating protein
kinase C. PMA treatment has been shown to lead to phosphory-
lation of C/EBPP, induce its translocation to the nucleus, and
enhance its ability to stimulate transcription (31, 39), sug-
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Figure 5. Dominant-negative C/EBPf3 inhibits TNFa promoter activa-
tion in Jurkat T cells. These experiments were performed as described
in Fig. 2 except that in addition to the TNFa reporter (3 ptg) and the
hC/EBP,3 (0.5 [Lg) expression plasmids, the DN C/EBPJ3 (DN229) or
vector (pCDM8) plasmids were cotransfected in the indicated quantities.
Relative light units were corrected for the total protein in the cell lysates.
Percent suppression was determined by comparison with the control
vector. These experiments were repeated three times with similar results.
TNFa activation (49), and whether the TNFa gene can be
activated in the absence of C/EBPI, for example in other cell
types that do not express the factor, remains to be determined.
In addition to TNFa, a number of other cytokine genes,
such as IL-1, IL-6, IL-8, and MIP-la also possess functional
C/EBP/3-binding sites in their promoters (24, 30, 32-35).
Many of these are considered important mediators of inflamma-
tion and are produced in response to TNFa (3-6). The expres-
sion of C/EBPJ may be important in chronic inflammation
associated with a variety of disorders. The inhibition of C/
EBP/3 activity, perhaps mediated by ectopic expression of a
dominant-negative form of the protein, presents a potential
means of blocking the synthesis of cytokines like TNFa which
contribute to chronic inflammation. Further work with domi-
nant-negative forms of C/EBP,[ will be required to determine
if such therapy is possible.
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